Arthropod-borne flaviviruses cause a wide range of important human diseases for which there are no specific therapies. To address this critical shortfall in preparedness to confront these emerging and re-emerging viruses, the goal of this proposal is to discover novel drug targets and develop new antiviral therapies that can be used broadly to treat a variety of flaviviral infections. A partnership of four independent academic laboratories, two at Duke Univeristy and two at the University of Virginia, will attack crucial aspects of pre- clinical drug development, as organized into the following specific aims: (1) Identification of high-quality targets for pan-flaviviral therapeutics. In this aim, three independent yet complementary approaches will be used to identify cellular targets for broad-spectrum therapies capable of treating a diverse group of flaviviral illnesses. These include genome-scale RNAi screens to identify novel host factors required for flaviviral infection, mining of the human """"""""purinome"""""""" to find purine-binding proteins that support infection, and application of a yeast-based drug discovery platform for the identification of novel targets. (2) Chemical screens for inhibitors of flavivirus replication. Targets identified in Aim 1 will be evaluated, and a subset will subjected to small molecule library screens using proteome mining and yeast-based methodologies. Priority will be given to compounds showing broad-spectrum activity including efficacy against mosquito-borne flaviviruses. (3) SAR and medicinal chemistry to define pan anti-flaviviral inhibitors. Up to six independent medicinal chemistry programs will be carried forward based on the most attractive products of the screens from Aim 2. Lead compounds will be optimized for potency of in vitro binding and efficacy in tissue culture models. (4) Pre-clinical testing. Established mouse models of YFV and WNV infection and newly established models of DENV infection will be used for maximum tolerated dose and initial pharmacological and efficacy studies. Flaviviruses are an emerging threat to public health in the US, a current risk to our armed forces and other citizens deployed around the world, and a major problem globally. At this time there is little that can be done to prevent or treat the majority of flaviviral infections and therefore development of broad-spectrum anti-flaviviral drugs is of crucial importance.

Public Health Relevance

Flaviviruses, which cause diseases like dengue fever and West Nile encephalitis, are emerging and re-emerging threats to public health in the US and the world. There are vaccines for only a small number of these viral infections and approved therapies for none. We propose to discover and develop new drugs capable of combating most, if not all, flaviviral pathogens.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI089526-03
Application #
8277243
Study Section
Special Emphasis Panel (ZAI1-FDS-M (M1))
Program Officer
Tseng, Christopher K
Project Start
2010-06-01
Project End
2015-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
3
Fiscal Year
2012
Total Cost
$835,261
Indirect Cost
$186,392
Name
Duke University
Department
Genetics
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Soto-Acosta, Ruben; Xie, Xuping; Shan, Chao et al. (2018) Fragile X mental retardation protein is a Zika virus restriction factor that is antagonized by subgenomic flaviviral RNA. Elife 7:
Haystead, T A J (2018) Fluorescent-Linked Enzyme Chemoproteomic Strategy (FLECS) for Identifying HSP70 Inhibitors. Methods Mol Biol 1709:75-86
Reid, David W; Campos, Rafael K; Child, Jessica R et al. (2018) Dengue Virus Selectively Annexes Endoplasmic Reticulum-Associated Translation Machinery as a Strategy for Co-opting Host Cell Protein Synthesis. J Virol 92:
Barrows, Nicholas J; Campos, Rafael K; Powell, Steven T et al. (2016) A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. Cell Host Microbe 20:259-70
Howe, Matthew K; Speer, Brittany L; Hughes, Philip F et al. (2016) An inducible heat shock protein 70 small molecule inhibitor demonstrates anti-dengue virus activity, validating Hsp70 as a host antiviral target. Antiviral Res 130:81-92
Alwarawrah, Yazan; Hughes, Philip; Loiselle, David et al. (2016) Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2(+) Breast Cancer. Cell Chem Biol 23:678-88
Gokhale, Nandan S; McIntyre, Alexa B R; McFadden, Michael J et al. (2016) N6-Methyladenosine in Flaviviridae Viral RNA Genomes Regulates Infection. Cell Host Microbe 20:654-665
Lu, Yi-Fan; Mauger, David M; Goldstein, David B et al. (2015) IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance. Sci Rep 5:16037
Manokaran, Gayathri; Finol, Esteban; Wang, Chunling et al. (2015) Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness. Science 350:217-21
Howe, Matthew K; Bodoor, Khaldon; Carlson, David A et al. (2014) Identification of an allosteric small-molecule inhibitor selective for the inducible form of heat shock protein 70. Chem Biol 21:1648-59

Showing the most recent 10 out of 18 publications